Weight, honestly/Compounds
The Fat-Burning Peptide That Couldn't Beat a Dummy Pill
AOD-9604 is sold as the fat-burning slice of growth hormone. Its biggest human trial says the real star was the meal plan.
Inspired Labs Editorial/Oct 17, 2026/10 sources

The Fat-Burning Peptide That Couldn't Beat a Dummy Pill
It's 9 p.m. and a clinic ad pops up on your phone: "The fat-burning piece of growth hormone, without the side effects." It sounds like a cheat code. Science even ran the test.
Here's the twist. In the biggest trial of that exact peptide, the thing that actually worked was the meal plan. So let's start there.
What actually moves the scale?
Not one magic thing. The US Preventive Services Task Force, the expert panel behind many checkup guidelines, reviewed the trials. Its verdict: intensive programs that coach people on food, movement and habits over many sessions lead to real, meaningful weight loss. The harms? Small to none.
Sleep turns out to matter too. In a University of Chicago trial, 80 adults with overweight who usually slept under six and a half hours got one coaching session on better sleep. They slept about an hour more a night.
Over two weeks, without being told to diet, they ate roughly 270 fewer calories a day than the comparison group. That's about a cookie and a half, gone, just from going to bed.
The everyday list, from those studies and US activity guidelines:
Get structured help, like a registered dietitian or a program with regular check-ins.
Move most days. The guidelines aim for about 150 minutes a week of brisk activity.
Protect your sleep. Short sleepers who added an hour ate less without trying.
If you're curious about weight-loss medicine, that's a talk with your clinician, not your feed.
Boring? Extremely. Also the only items on this page with big human trials behind them.
Wait, a piece of growth hormone?
Yep. Growth hormone is a long protein chain, 191 building blocks. It does two big jobs at once: it helps things grow, and it nudges fat cells to release stored fat.
Think of it as a TV remote with a lot of buttons. In the 1990s, researchers in Melbourne wondered if they could pry off just the "burn fat" button. They copied the tail end of the hormone, swapped one building block at the front, and called it AOD9604.
In obese mice, it looked great. Two weeks of it slowed weight gain and raised markers of fat burning. Unlike full growth hormone, it didn't mess with blood sugar or latch onto the growth hormone receptor. That's a real, published lab result. It's also mice.
So what happened in people?
An Australian company, Metabolic Pharmaceuticals, ran six placebo-controlled trials. The safety side looked clean. Researchers tied to the company reported no rise in the growth marker IGF-1, no blood sugar trouble, and side effects that matched the dummy pill.
An early 12-week tablet trial reported a bit more weight loss than placebo. When FDA reviewers went looking in 2024, though, they couldn't find a published paper with its methods and full results.
Then came the big test. About 500 adults with obesity at 16 sites took a daily tablet of AOD9604 or a dummy pill for 24 weeks. Everyone also got a dietitian-supervised diet and exercise program.
The result: on top of the program, the drug added less than 1 kg, about 2 pounds, at every dose. That gap was too small to count. In February 2007, the company shut the obesity program down.
Its announcement had a remarkable line. The placebo group lost so much weight that the drug's effect "may have been overwhelmed by the effective weight loss programme."
The tablet didn't lose to nothing. It lost to a dietitian.
What about the shots clinics sell?
Here's the awkward part. Both big trials used tablets. When FDA reviewers searched in 2024, they found no human studies of AOD9604 injected under the skin, or used as a cream.
The closest was a small trial that put it in a vein for a few weeks. The weight change wasn't different from placebo.
That December, an FDA advisory panel voted 12 to 0 against letting compounding pharmacies use it. FDA's safety page still flags possible immune reactions, impurity questions, and serious side effects with an unclear cause. It isn't an FDA-approved drug.
A button pried off a remote doesn't always change the channel.
Literature, not lore.
If you remember one thing…
The most-tested "fat-burning peptide" couldn't beat a dummy pill in its biggest trial, because the meal plan did the heavy lifting. Structured help, regular movement and real sleep are the habits with receipts.
Everything Inspired Labs carries is Research Use Only: lab material, not a weight-loss treatment, and not for your body. Nothing here is medical advice.
Sources
- 01Behavioral weight loss interventions to prevent obesity-related morbidity and mortality in adults: USPSTF recommendation statement — US Preventive Services Task Force; Curry SJ, Krist AH, Owens DK, et al (2018). JAMA.
Guidance (intensive, multicomponent behavioral interventions lead to clinically significant weight improvement; harms "small to none"; B recommendation for adults with BMI 30+).
- 02Effect of sleep extension on objectively assessed energy intake among adults with overweight in real-life settings: a randomized clinical trial — Tasali E, Wroblewski K, Kahn E, Kilkus J, Schoeller DA (2022). JAMA Intern Med.
Human-rct (80 adults, age 21–40, BMI 25–29.9, habitual sleep under 6.5 h; one sleep-hygiene counseling session; about 1.2 h more sleep per night; energy intake down about 270 kcal/day vs control over a 2-week intervention; no prescribed diet).
- 03US Department of Health and Human Services (2018). Physical Activity Guidelines for Americans, 2nd edition.
Guidance (adults: 150–300 minutes a week of moderate-intensity aerobic activity).
- 04Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment — Heffernan MA, Thorburn AW, Fam B, et al (2001). Int J Obes Relat Metab Disord.
Preclinical (ob/ob mice, 14 days by osmotic pump; reduced weight gain, raised fat oxidation and plasma glycerol; unlike hGH, no hyperglycaemia, no hGH-receptor binding, no cell proliferation; Monash University).
- 05The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and β3-AR knock-out mice — Heffernan M, Summers RJ, Thorburn A, et al (2001). Endocrinology.
Preclinical (chronic effects absent in β3-adrenergic receptor knockout mice).
- 06Safety and tolerability of the hexadecapeptide AOD9604 in humans — Stier H, Vos E, Kenley D (2013). J Endocrinol Metab.
Human-rct safety synthesis (six randomized, double-blind, placebo-controlled trials; no effect on IGF-1; no negative effect on glucose tolerance; no anti-AOD9604 antibodies in assayed samples; tolerability "indistinguishable from placebo"; company-linked authors).
- 07"Metabolic's obesity drug – Phase 2B clinical trial results" (ASX announcement, Melbourne, Feb 21, 2007), filed with the SEC — Metabolic Pharmaceuticals Ltd (2007). Metabolic Pharmaceuticals Ltd.
Human-rct (OPTIONS: 536 enrolled, ~500 randomized, BMI 30–45, age 18–65, 16 Australian sites; weight loss beyond the program "was less than 1 kg in all dose groups"; primary endpoint not met; "drug effects were overwhelmed by the effective weight loss programme"; "Development of the drug for this condition is terminated").
- 08FDA Briefing Document, Pharmacy Compounding Advisory Committee, December 4, 2024 — AOD-9604-related bulk drug substances — US Food and Drug Administration (2024). US Food and Drug Administration.
Regulatory (earlier 12-week oral trial: "We did not locate a publication of the study methods and results"; 23-adult IV study, 0.58 kg over 3 weeks, not different from placebo; no human data found for subcutaneous or transdermal use; no AOD-9604 studies on ClinicalTrials.gov).
- 09Final Summary Minutes of the Pharmacy Compounding Advisory Committee Meeting, December 4, 2024 — US Food and Drug Administration (2024). US Food and Drug Administration.
Regulatory (AOD-9604 free base and acetate: Yes 0, No 12, Abstain 0 on placing them on the 503A Bulks List).
- 10Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of 04/22/2026) — US Food and Drug Administration (2026). US Food and Drug Administration.
Regulatory (AOD-9604 listed under "nominated but withdrawn"; immunogenicity, peptide-impurity and characterization concerns; "serious adverse events that may be associated with AOD-9604, though causality is not clear").
Educational material for laboratory research context only. Nothing here is medical advice, a protocol for human use, or a claim that Inspired Labs products diagnose, treat, cure, or prevent disease.
Continue

Your Muscle Noticed Menopause. Science Still Points at Iron.
After menopause, honestly
Your Muscle Noticed Menopause. Science Still Points at Iron.
Read brief → 3 min

Your Tendons Are Still Running on Your Teenage Collagen
Recovery, honestly
Your Tendons Are Still Running on Your Teenage Collagen
Read brief → 3 min

The Holiday Pound Is Small. It Just Never Leaves.
Weight, honestly
The Holiday Pound Is Small. It Just Never Leaves.
Read brief → 3 min

